Dishman Carbogen Amcis Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹507 Cr −22.3% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
DC

Dishman Carbogen Amcis Ltd

Q4 FY25Pharmaceuticals & Biotechnology

Dishman Carbogen Amcis Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹716Cr
+9.3% YoY
+5% QoQ
Net profit
₹43Cr
Turned profitable YoY
+760% QoQ
Margin
21%
+11 pp YoY
0 pp QoQ

Dishman Carbogen Amcis Ltd Q4 FY25 key numbers

Revenue
Peak revenue from India assets could reach around INR 800 crores within 2 to 3 years.

As stated in Dishman Carbogen Amcis Ltd's Q4 FY25 earnings call transcript · published 14 Jun 2026. Reported figures, not investment advice.

Price₹174
Market cap₹3.0K Cr
P/E164.8

The short version

The company targets a low double-digit revenue growth, aiming for a CAGR of 12% to 15% over the next 3 to 5 years. EBITDA for FY '26 is expected between INR 550 crores to INR 570 crores, targeting a 20% margin.

From Dishman Carbogen Amcis Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company targets a low double-digit revenue growth, aiming for a CAGR of 12% to 15% over the next 3 to 5 years. (Page 10)
  • India CRAMS business is expected to grow by 15% to 20% in FY ‘26. (Page 9)
  • The Quats and Generics business is expected to grow between 5% to 10%. (Page 9)
  • Peak revenue from India assets could reach around INR 800 crores within 2 to 3 years. (Pages 13-14)
  • Bavla site's quarterly revenue is anticipated to reach around INR 100 crores in the later part of FY ‘26. (Page 15)
  • EBITDA targeted at INR 550 crores to INR 570 crores in FY ‘26, with potential for higher margins than 20%. (Page 22)

2 more points from Dishman Carbogen Amcis Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Dishman Carbogen Amcis Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY ‘26 CAPEX guidance is approximately INR 250 crores to INR 300 crores (EUR 25-30 million).
  • Maintenance CAPEX is around INR 170-180 crores; the remainder is growth CAPEX including digital transformation initiatives.
  • Large CAPEX for the French entity is mostly behind; future CAPEX will focus on expansion based on confirmed business cases.
  • Co-investment of EUR 25 million by a Japanese customer for a specific project; infrastructure investment is a core investment paid by the client.
  • Additional investments are planned in product expansion projects in Europe and India.
  • Focus on CAPEX only when there is committed revenue from customers to ensure returns.

2 more points from Dishman Carbogen Amcis Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Dishman Carbogen Amcis Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The discussion indicates a positive outlook on upcoming projects, with a focus on early-phase and late-phase (Phase IIb and Phase III) projects.
  • The company is investing in market intelligence to identify new opportunities and potentially become a secondary supplier for risk mitigation.
  • There is a mention of strong interest and investment in the CRAMS business and API development with expected growth.

2 more points from Dishman Carbogen Amcis Ltd's call on order book

Create a free account to keep reading this call

Dishman Carbogen Amcis Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Dishman Carbogen Amcis Ltd Q4 FY25 results — key figures

Dishman Carbogen Amcis Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue716655+9.3%682+5%
Operating profit (EBITDA)15363+142.9%140+9.3%
Operating margin21%10%+11 pp21%0 pp
Profit before tax28-49—27+3.7%
Net profit (PAT)43-70—5+760%
EPS (₹)2.75-4.46—0.30+816.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹507 Cr, net loss ₹67 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Lincoln Pharmaceuticals (Q4 FY25)

    Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Dishman Carbogen Amcis Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Dishman Carbogen Amcis Ltd Q4 FY25 results?

The company targets a low double-digit revenue growth, aiming for a CAGR of 12% to 15% over the next 3 to 5 years. EBITDA for FY '26 is expected between INR 550 crores to INR 570 crores, targeting a 20% margin.

What is Dishman Carbogen Amcis Ltd share price analysis?

Dishman Carbogen Amcis Ltd currently shows a neutral. The stock trades at a P/E of 164.8 with a market cap of ₹2,989 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dishman Carbogen Amcis Ltd planning capital expenditure?

FY ‘26 CAPEX guidance is approximately INR 250 crores to INR 300 crores (EUR 25-30 million).

Keep Dishman Carbogen Amcis Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.